OHSU

Bill Hoon Chang, M.D., Ph.D.

Head Shot of Bill Chang

Background

Dr. Chang's research focuses on understanding the biochemical mechanism responsible for resistance in refractory and relapse leukemias. Identifying these mechanisms will aid in the development of new therapies for these resistant diseases. Using RNA interference technologies he has been able to identify new biochemical targets for therapy. Dr. Chang's research continues in collaboration with the Children's Oncology Group to develop these targets for new therapies to these cancers.


Selected Publications

"RNAi screen for rapid therapeutic target identification in leukemia patients.," Proceedings of the National Academy of Sciences of the United States of America (Vol: 106, Issue: 21, Page 8695-700) - 2009

"Management of menstrual bleeding and cycle control after hematopoietic stem cell transplant.," International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (Vol: 100, Issue: 1, Page 76-7) - 2008

"A unique case of adolescent CD56-negative extranodal NK/T-cell lymphoma, nasal type.," Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society (Vol: 11, Issue: 1, Page 50-4) - 2008

"Chromosomes with delayed replication timing lead to checkpoint activation, delayed recruitment of Aurora B and chromosome instability.," Oncogene (Vol: 26, Issue: 13, Page 1852-61) - 2007

"p300/CREB-binding protein interacts with ATR and is required for the DNA replication checkpoint.," The Journal of biological chemistry (Vol: 282, Issue: 13, Page 9678-87) - 2007

 

Back to faculty list

OHSU Doernbecher Children's Hospital

Visit Our Site

For Healthcare Professionals


Contact

  Email Bill Chang

503 418-5150

Memberships & Associations

American Academy of Pediatrics, American Society of Pediatric Hematology and Oncology, American Society of Hematology, American Society of Clinical Oncology, American Society for Blood and Marrow Transplantation, American Association for Cancer Research